- •Genetic mutations in SH2B3 associate with higher hemoglobin levels in humans
- •Suppression of SH2B3 in HSPCs improves erythroid expansion and differentiation
- •SH2B3 suppression does not impair the production of fully mature RBCs
- •SH2B3 inactivation by genome editing in PSCs increases erythroid expansion
Targeted Application of Human Genetic Variation Can Improve Red Blood Cell Production from Stem Cells
Multipotent and pluripotent stem cells are potential sources for cell and tissue replacement therapies. For example, stem cell-derived red blood cells (RBCs) are a potential alternative to donated blood, but yield and quality remain a challenge. Here, we show that application of insight from human population genetic studies can enhance RBC production from stem cells. The SH2B3 gene encodes a negative regulator of cytokine signaling and naturally occurring loss-of-function variants in this gene increase RBC counts in vivo. Targeted suppression of SH2B3 in primary human hematopoietic stem and progenitor cells enhanced the maturation and overall yield of in-vitro-derived RBCs. Moreover, inactivation of SH2B3 by CRISPR/Cas9 genome editing in human pluripotent stem cells allowed enhanced erythroid cell expansion with preserved differentiation. Our findings therefore highlight the potential for combining human genome variation studies with genome editing approaches to improve cell and tissue production for regenerative medicine.
To access this article, please choose from the options below
Purchase access to this article
You must be logged in to purchase this article.
If you are a current subscriber with Society Membership or an Account Number, claim your access now.
Subscribe to this title
Purchase a subscription to gain access to this and all other articles in this journal.
Visit ScienceDirect to see if you have access via your institution.